报告人：Hélder A. Santos, D.Sc.

报告时间：2017年10月20日8:30-9:30；

报告地点：生科院二楼大会议室

邀请人：杨祥良教授、李子福教授

报告人个人简介：

Dr. Hélder A. Santos (D.Sc. Tech., Chem. Eng.) received his doctorate degree (2007) in Chemical Engineering from Helsinki University of Technology, Finland. Currently, an Associate Professor (tenure track) in Pharmaceutical Nanotechnology, Head of the Research Unit Pharmaceutical Nanotechnology and Chemical Microsystems, and Head of the Preclinical Drug Formulation and Analysis Group at the Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki (Finland). He is also a Fellow member of the recently established Helsinki Institute of Life Science (HiLIFE). Dr. Santos' research interests include the development of nanoparticles/nanomedicines for biomedical and healthcare applications. His current work makes the bridge between engineering, pharmaceutical and medical research. His main research focus is in the use of biodegradable and biocompatible nanoporous silicon nanomaterials, polymers, the application of microfluidics technology for nanoparticle production for simultaneous controlled drug delivery, diagnostic and treatment of cancer, diabetes, and cardiovascular diseases, and further translation of these nanotechnologies into the clinic. Dr. Santos' is author of more than 195 publications in prestigious, high impact, peer-reviewed publications, such as Advanced Materials, ACS Nano, Advanced Functional Materials, Chemistry of Materials, Biomaterials, Small, etc. He has given over 110 invited talks at prestigious conferences, universities and summer schools around the world. Dr. Santos is also an Editorial Board Member for several international peer-reviewed journals, and the Editor and founder of the Mesoporous Biomaterials journal, Academic Editor of PLOS ONE, BioMed Research International, Journal of Healthcare Engineering, and Advances in Materials Science and Engineering, as well as author of the book "Porous Silicon for Biomedical Applications". Moreover, he has received a number of prestigious awards and grants, such as the "Talent Prize in Science" attributed by the Portuguese government in 2010, the European Research Council Starting Grant in 2013, the Young Researcher Award in 2013 and honour distinction for the exceptional scientific productivity in 2014, both attributed by the Faculty of Pharmacy at the University of Helsinki, as well as the Academy of Finland Award for Social Impact in 2016.

Talk Title: Multifunctional Nanoparticles For Biomedical Applications

Abstract: Novel biomedical engineering technologies have been underlined as very promising means for the advance in medical research [1–3]. Personalized medicine allows for the identification of the right therapy, reaching the right therapeutic target in the body at the right time in an efficient manner, with reduced undesired collateral effects [4]. In this context, target nanomedicines are of great interest towards the development of personalized medicines and envisaged for their large-scale implementation. Recently, we have developed prominent biomaterials, such as porous silicon and polymer-based micro/nano-particles as potential platforms for cancer theranostics and other individualization of medical intervention [5–13]. All these biomaterials are promising advanced drug delivery technologies for biomedical applications. The results of the efficient surface biofunctionalization, targeting, imaging, encapsulation of drug molecules using advanced technologies, such the microfluidics technique, are presented and discussed in detail. Examples on how these materials can be used to enhance the bioavailability of drug/peptide molecules, demonstrating their cytocompatibility, in vivo biofate (imaging) and intracellular targeting for different diseases (e.g., cancer, diabetes, and neural and cardiovascular diseases), are also presented. Overall, the recent cutting-edge advances on nanomaterials are anticipated to overcome some of the therapeutic window and clinical applicability of many drug/peptide molecules, and can also act as innovative theranostic platforms and tools for the clinic, because they offer a less invasive alternative compared to the conventional therapeutic strategies and, thereby, enhancing the expectancy and quality of life of the patients.

1. H.A. Santos, J. Hirvonen, Nanomedicine (London) 7 (2012) 1281.

2. N. Shrestha, et al. Biomaterials 68 (2015) 9.

3. H.A. Santos, Porous Silicon For Biomedical Applications. Elsevier Ltd. 2014.

4. H.A. Santos, et al. Nanomedicine (London) 9 (2014) 535.

5. F. Araújo, et al. ACS Nano 9 (2015), 8291;

6. F. Kong, et al. Adv. Funct. Mater. 25 (2015) 3330.

7. H. Zhang, et al. Adv. Mater 26 (2014) 4497.

8. D. Liu, et al. Adv. Mater. 27 (2015) 2298.

9. D. Liu, et al. Biomaterials 39 (2015) 249.

10. D. Liu, et al. Nano Lett. 17 (2017) 606.

11. F. Fontana, et al. Adv. Mater. 2017. DOI: 10.1002/adma.201603239.

12. V. Balasubramanian, et al. Adv. Mater. 2017. DOI: 10.1002/adma.201605375.

13. C.-F. Wang, Biomaterials 48 (2015) 108.